Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

BACKGROUND: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CL(pro)) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19. METHODS: This was a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fuxiang, Xiao, Wen, Tang, Yimin, Cao, Mengli, Shu, Dan, Asakawa, Tetsuya, Xu, Yechun, Jiang, Xiangrui, Zhang, Leike, Wang, Wei, Tang, Jianxing, Huang, Yuansheng, Yang, Yang, Yang, Yumei, Tang, Renhong, Shen, Jingshan, Lu, Hongzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362366/
https://www.ncbi.nlm.nih.gov/pubmed/37484496
http://dx.doi.org/10.1016/j.lanwpc.2023.100835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362366/
https://www.ncbi.nlm.nih.gov/pubmed/37484496
http://dx.doi.org/10.1016/j.lanwpc.2023.100835

Ejemplares similares